Considering the trial isn't until early 2022, I will end up making a DD explaining IMT504 and will prolly explain why I think it'll work or not before the trial, sometime early next year or later this year.
Orphan drugs are usually fast tracked and grant funded by government programs. This has been explained in a few PRs already. Receiving the NIH license is a precursor to everything else falling into place. Don't see dilution here unless there's an expense that has yet to come to light in terms of operational costs, fees or other.
News 
Market Data 
Discover 
